Assess Risks of Gene Therapy in Follow-Up Study: FDA Panel Assess Risks of Gene Therapy in Follow-Up Study: FDA Panel

A panel of advisers to the regulator said on Tuesday Vertex Pharmaceuticals and CRISPR Therapeutics could assess potential safety risks of their sickle cell disease gene therapy after approval.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news